Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

The Almond Yogurt Study (AYS) (AYS)

16 novembre 2026 aggiornato da: Amanda Wright, Ph.D., University of Guelph

The Impact of Almond Food Structure in a Standardized Yogurt Breakfast Meal on Gastric Emptying, Oral Processing Behaviours, Appetite-Regulating Hormones, Postprandial Metabolism, and Subjective Satiety: A Randomized Crossover Trial

The goal of this clinical trial is to explore how almond food structure influences gastric emptying rates when consumed by healthy adult women as part of a standardized breakfast meal. The main questions it aims to answer are:

  • Does the structure of almonds (whole, chopped, buttered) influence gastric emptying ?
  • What is the correlation between chewing behaviour, gastric emptying, and changes in postprandial triacylglycerols and satiety (hormones and ratings) within the context of an increasingly disrupted nut matrix.

Panoramica dello studio

Descrizione dettagliata

This study is investigating how the structure of almonds (whole, chopped, buttered) as part of a yogurt-based breakfast meal influences gastric emptying and postprandial metabolism. Over three randomized visits, fasted healthy adult female participants will arrive at the research centre where an iv-catheter will be inserted for serial blood sampling over 6 hours for analysis of plasma triacylglycerols, GLP-1, CCK, glucose, and insulin. Participants will consume each meal while being video recorded to quantify chewing frequency and eating time. Paper questionnaires will periodically assess participants' eating experiences and hunger sensations throughout the visit (e.g., exertion, liking, hunger, fullness). Gastric ultrasonography will be used to visualize and quantify the cross-sectional area of the gastric antrum so that changes in gastric volume can be tracked over time. Overall, this study aims to determine how almond form, as an example of food structure, influences chewing, gastric emptying, satiety and postprandial metabolism.

Tipo di studio

Interventistico

Iscrizione (Stimato)

25

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

    • Ontario
      • Guelph, Ontario, Canada, N1G 2G4
        • Department of Human Health Sciences
        • Contatto:
        • Contatto:
          • Alison M Duncan, PhD
        • Investigatore principale:
          • Amanda J Wright, PhD

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 45 anni (Adulto)

Accetta volontari sani

Sì

Sessi ammissibili allo studio

Femmina

Descrizione

Inclusion Criteria:

  • Healthy female adults aged 18-45 years.
  • Body Mass Index (BMI) between 18.5-27.9 kg/m2, or waist circumference of less than 88 cm
  • Visible gastric antrum on ultrasound
  • No known food allergies or sensitivities
  • Non restrained eaters (TFEQ, see below)
  • No history of gastrointestinal diseases that may interfere with eating behavior or digestion
  • Not on medications that affect appetite (including GLP-1 agonists), digestion, blood sugar regulation, saliva production, or chewing
  • Stable medication use
  • Non-smokers
  • Not gained or lost significant weight during the past 3 months
  • Regular monthly menstrual cycles
  • Not pregnant, lactating or post-menopausal

Exclusion Criteria:

  • Diabetes or other metabolic disorders affecting glycemia and overall cardiometabolic health
  • Blood pressure > 140/90 mm Hg
  • Any food allergies, intolerances, or sensitivities
  • Pregnant or breastfeeding
  • Participation in another clinical trial
  • Excessive alcohol consumption (more than 14 drinks per week)
  • Smokers or those with a smoking history of more than 10 years
  • Regular use of recreational drugs (e.g., marijuana, ecstasy, LSD, magic mushrooms, etc.)
  • Restrained eater (>16) as defined by the questionnaire at screening (Three-Factor Eating Questionnaire, Stunkard et al., 1985)
  • Unusual sleep patterns
  • Irregular breakfast consumption
  • Recent weight changes, or intended weight loss or gain; lost/gained 10% of body weight within the last 6 months
  • Food allergies/sensitivities or any life-threatening allergies
  • Using medications known to affect appetite, digestion, blood sugar regulation, or chewing/swallowing (excluding oral contraceptives).
  • Experiences dry mouth in general or due to medication side effects
  • Inability to adhere to study protocols
  • Not comfortable providing IV-line blood samples
  • Not comfortable providing ultrasound scans
  • Not comfortable being video recorded while eating
  • Avoids consuming almonds/yogurt in general
  • Avoids eating hard foods to prevent dental fractures

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Scienza basilare
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione incrociata
  • Mascheramento: Doppio

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Whole - Chopped - Buttered

Participants consume 115 g vanilla yogurt with 60 g whole almonds at the first intervention visit, chopped almonds at the second intervention visit, and almonds processed into almond butter at the third intervention visit.

Breakfast meal consisting of vanilla yogurt (115g) with almonds (60g) in different forms.

Sperimentale: Whole - Buttered - Chopped

Participants consume 115 g vanilla yogurt with 60 g whole almonds at the first intervention visit, buttered almonds at the second intervention visit, and chopped almonds at the third intervention visit.

Breakfast meal consisting of vanilla yogurt (115g) with almonds (60g) in different forms.

Sperimentale: Buttered - Whole - Chopped

Participants consume 115 g vanilla yogurt with 60 g buttered almonds at the first intervention visit, whole almonds at the second intervention visit, and chopped almonds at the third intervention visit.

Breakfast meal consisting of vanilla yogurt (115g) with almonds (60g) in different forms.

Sperimentale: Buttered - Chopped - Whole

Participants consume 115 g vanilla yogurt with 60 g buttered almonds at the first intervention visit, chopped almonds at the second intervention visit, and whole almonds at the third intervention visit.

Breakfast meal consisting of vanilla yogurt (115g) with almonds (60g) in different forms.

Sperimentale: Chopped - Buttered - Whole

Participants consume 115 g vanilla yogurt with 60 g chopped almonds at the first intervention visit, buttered almonds at the second intervention visit, and whole almonds at the third intervention visit.

Breakfast meal consisting of vanilla yogurt (115g) with almonds (60g) in different forms.

Sperimentale: Chopped - Whole - Buttered

Participants consume 115 g vanilla yogurt with 60 g chopped almonds at the first intervention visit, whole almonds at the second intervention visit, and buttered almonds at the third intervention visit.

Breakfast meal consisting of vanilla yogurt (115g) with almonds (60g) in different forms.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Gastric emptying half-time
Lasso di tempo: At each study visit, based on assessments at 0, 0.5, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Calculated from ultrasound imaging of the gastric antrum cross-sectional area at baseline (fasted) and after consumption of the breakfast meal, in minutes

At each study visit, based on assessments at 0, 0.5, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Eating time
Lasso di tempo: From 0 minutes until the end of eating the breakfast meal

The time to consume the breakfast meal based on video recordings, in minutes

From 0 minutes until the end of eating the breakfast meal
Changes from baseline in postprandial satiety visual analogue scale ratings
Lasso di tempo: 0, 0.5, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Paper questionnaire scale ratings (in mm) of Hunger, Fullness, Prospective Consumption, and Desire to Eat where each is 100 mm ranging from 0 (minimum) to 100 (maximum). For example, 0 = Not at all Hungry and 100 = As Hungry as Possible.

0, 0.5, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
Changes from baseline in plasma triacylglycerol concentration
Lasso di tempo: 0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Based on analysis of serial blood draws, in mmol/L

0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
Triacylglycerol response - incremental area under the curve (AUC)
Lasso di tempo: 0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Calculated based on baseline and postprandial plasma concentrations

0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
Changes from baseline in plasma GLP-1 concentration
Lasso di tempo: 0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Based on analysis of serial blood draws, in pg/mL

0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
GLP-1 response - incremental area under the curve (AUC)
Lasso di tempo: 0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Calculated based on baseline and postprandial plasma concentrations

0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
Changes from baseline in plasma CCK concentration
Lasso di tempo: 0, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Based on analysis of serial blood draws, in pmol/L

0, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
CCK response - incremental area under the curve (AUC)
Lasso di tempo: 0, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Calculated based on baseline and postprandial plasma concentrations

0, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
Changes from baseline in gastric volume
Lasso di tempo: 0, 0.5, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Calculated based on ultrasound imaging of the gastric antrum cross-sectional area at baseline (fasted) and after eating the breakfast meal, in mL

0, 0.5, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
Gastric volume - incremental area under the curve (AUC)
Lasso di tempo: 0, 0.5, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Based on ultrasound imaging of the gastric antrum cross-sectional area at baseline (fasted) and after eating the breakfast meal

0, 0.5, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Borg rating of perceived exertion
Lasso di tempo: Immediately after the breakfast meal is consumed

Participant paper scale rating of effort required to chew the breakfast meal where 0 = No effort at all and 10 = Very very severe chewing effort

Immediately after the breakfast meal is consumed
Changes from baseline in plasma blood glucose concentration
Lasso di tempo: 0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Based on analysis of serial blood draws, in mmol/mL

0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
Glucose response - incremental area under the curve (AUC)
Lasso di tempo: 0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Calculated based on baseline and postprandial plasma concentrations

0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
Changes from baseline in plasma blood insulin concentration
Lasso di tempo: 0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Based on analysis of serial blood draws, in pmol/mL

0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
Insulin response - Area under the curve (AUC)
Lasso di tempo: 0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Calculated based on baseline and postprandial plasma concentrations

0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
Product liking and perceived attributes
Lasso di tempo: Immediately after eating the breakfast meal

Participant paper scale questionnaire ratings

Immediately after eating the breakfast meal
Eating rate
Lasso di tempo: From 0 minutes until the end of eating the breakfast meal

Calculated from video recordings of eating session, combining meal portion consumed (in grams) and eating time (minutes), grams/minute

From 0 minutes until the end of eating the breakfast meal
Number of chews
Lasso di tempo: From 0 minutes until the end of eating the breakfast meal

Determined by count from video recordings of each eating session

From 0 minutes until the end of eating the breakfast meal

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

15 novembre 2026

Completamento primario (Stimato)

15 dicembre 2027

Completamento dello studio (Stimato)

19 dicembre 2027

Date di iscrizione allo studio

Primo inviato

29 ottobre 2026

Primo inviato che soddisfa i criteri di controllo qualità

16 novembre 2026

Primo Inserito (Effettivo)

18 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

18 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

16 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • ID3014
  • 400819 (Altro numero di sovvenzione/finanziamento: Natural Sciences & Engineering Research Council of Canada)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

INDECISO

Descrizione del piano IPD

Although we are not required to make this data available, we are currently working to understand how to do this in a safe way, as per our institutional guidelines. As we learn more, we may pursue this. We are obtaining consent from study participants for this option.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi